Subscribe
shutterstock_1448545871_jhvephoto
JHVEphoto / Shutterstock.com
5 January 2021AmericasMuireann Bolger

Teva fails to reclassify MS drug to thwart generics

Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone (glatiramer acetate) as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Actavis and Teva sued over narcotic addiction generic
1 March 2017   Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.
Asia
Teva buys Allergan Generics in $40bn deal
27 July 2015   Pharmaceutical company Teva has bought Allergan Generics from drugs business Allergan in a $40.5 billion deal.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Actavis and Teva sued over narcotic addiction generic
1 March 2017   Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.
Asia
Teva buys Allergan Generics in $40bn deal
27 July 2015   Pharmaceutical company Teva has bought Allergan Generics from drugs business Allergan in a $40.5 billion deal.

More on this story

Americas
Actavis and Teva sued over narcotic addiction generic
1 March 2017   Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.
Asia
Teva buys Allergan Generics in $40bn deal
27 July 2015   Pharmaceutical company Teva has bought Allergan Generics from drugs business Allergan in a $40.5 billion deal.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility